Affected children are born with café-au-lait spots and sometimes Lisch nodules. During adolescence and young adulthood, more than 19% of affected individuals with NF1 develop cutaneous neurofibromas ...

Verastem Oncology (Nasdaq: VSTM), a biopharmaceutical company committed to advancing new medicines for patients with RAS/MAPK ...

For children with severe hypertrophic cardiomyopathy caused by gain-of-function RAS/mitogen-activated protein kinase (MAPK) mutations (RASopathy), trametinib reduces mortality and morbidity.

The future of skin cancer treatment looks even more promising. Advances in artificial intelligence (AI) are revolutionizing ...

High CDC20 expression promotes aneuploid cancer cell sensitivity to spindle assembly checkpoint (SAC) inhibition by ...

A phase 2a trial of IMM-1-104 plus chemotherapy demonstrated efficacy and tolerability in first- and second-line pancreatic ...

SpringWorks Therapeutics Inc . (NASDAQ:SWTX), a biotechnology company with a market capitalization of $2.66 billion focused ...

Pasithea Therapeutics opens European clinical trial sites and completes initial dosing of cohort 4: Miami Thursday, January 16, 2025, 12:00 Hrs [IST] Pasithea Therapeutics Corp., ...

Dual blocking SHP2 and FGFR2 can not only promote the targeted tumor-killing effects and overcome FGFR2 inhibitor resistance caused by feedback activation, but also activate T cell-mediated anti-tumor ...

This important study reveals a role for IκBα in the regulation of embryonic stem cell pluripotency. The solid data in mouse embryonic stem cells include separation of function mutations in IκBα to ...

We are thrilled to welcome Matt to Verastem Oncology at an important time as we prepare for a mid-2025 product launch and the transition into a commercial-stage company, while we continue to advance ...